The DF/HCC Program in Biostatistics and Computational Biology fosters a broad range of research into statistical, computational and mathematical questions that arise in cancer investigations. Its members are engaged in trans-disciplinary and inter-programmatic projects across population, clinical and basic cancer research. Biostatistics has been a Program since the formation of DF/HCC and was rated as outstanding at the time ofthe last CCSG renewal. The name ofthe Program was changed to Biostatistics and Computational Biology in 2010, with the support ofthe EAB, in order to recognize the strong contribution of computational biologists. This Program is led by G. Parmigiani and R. Betensky and has 45 members from all member institutions. Members are affiliated with two departments at HSPH (Biostatistics and Epidemiology) and six departments at HMS (Biological Chemistry and Molecular Pharmacology, Population Medicine, Medicine, Health Care Policy, Pediatrics and Radiation Oncology). The Program has two Specific Aims: 1) to develop and disseminate new tools in statistical science and computational biology that respond to emerging areas of cancer research;and 2) to develop software for the implementation of these tools. The Biostatistics and Computational Biology Program continues to be highly successful in securing external funding. In 2009, peer-reviewed grant funding attributed to the Program was $14.4 million in total costs, of which nearly $7 million was from NCI (49%) and $7.4 million was from other peer-reviewed sponsors. Attesting to the productivity and interactivity ofthe Program are the 1,666 publications authored by members during the project period, of which 4.2% were intra-programmatic, 44% were inter-programmatic and 33% were inter-institutional collaborations.
The DF/HCC Program in Biostatistics and Computational Biology fosters research into the mathematical, computational, and statistical questions that arise in cancer research. It supports methodological as well as inter-disciplinary and inter-programmatic research across population, clinical and basic cancer research.
|Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33|
|Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:|
|Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192|
|Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95|
|Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9|
|Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57|
|Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49|
|Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90|
|Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80|
|Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608|
Showing the most recent 10 out of 177 publications